The University of Chicago Header Logo

Connection

Michael Becker to Gout Suppressants

Back to Details
This is a "connection" page, showing publications Michael Becker has written about Gout Suppressants.
Michael Becker
Connection Strength
5.720
Gout Suppressants
  1. Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study). Arthritis Rheumatol. 2017 01; 69(1):203-212.
    View in: PubMed
    Score: 0.557
  2. An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Semin Arthritis Rheum. 2015 Oct; 45(2):174-83.
    View in: PubMed
    Score: 0.498
  3. Diabetes and gout: efficacy and safety of febuxostat and allopurinol. Diabetes Obes Metab. 2013 Nov; 15(11):1049-55.
    View in: PubMed
    Score: 0.435
  4. Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis. 2013 Sep 01; 72(9):1469-74.
    View in: PubMed
    Score: 0.418
  5. What do I need to know about gout? J Fam Pract. 2010 Jun; 59(6 Suppl):S1-8.
    View in: PubMed
    Score: 0.353
  6. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010; 12(2):R63.
    View in: PubMed
    Score: 0.349
  7. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009 Jun; 36(6):1273-82.
    View in: PubMed
    Score: 0.324
  8. Update on emerging urate-lowering therapies. Curr Opin Rheumatol. 2009 Mar; 21(2):143-9.
    View in: PubMed
    Score: 0.324
  9. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008 Jun; 27(6):585-91.
    View in: PubMed
    Score: 0.307
  10. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005 Dec 08; 353(23):2450-61.
    View in: PubMed
    Score: 0.259
  11. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol. 2004 Aug; 31(8):1575-81.
    View in: PubMed
    Score: 0.236
  12. Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. Arthritis Rheumatol. 2019 01; 71(1):143-153.
    View in: PubMed
    Score: 0.160
  13. Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study. Arthritis Res Ther. 2018 05 30; 20(1):99.
    View in: PubMed
    Score: 0.154
  14. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018 Mar 29; 378(13):1200-1210.
    View in: PubMed
    Score: 0.151
  15. Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment. Arthritis Rheumatol. 2016 08; 68(8):2035-43.
    View in: PubMed
    Score: 0.135
  16. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. J Clin Rheumatol. 2014 Dec; 20(8):427-32.
    View in: PubMed
    Score: 0.121
  17. Long-term management of gout: nonpharmacologic and pharmacologic therapies. Rheum Dis Clin North Am. 2014 May; 40(2):357-74.
    View in: PubMed
    Score: 0.114
  18. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Arthritis Care Res (Hoboken). 2012 Feb; 64(2):256-61.
    View in: PubMed
    Score: 0.099
  19. Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. Nucleosides Nucleotides Nucleic Acids. 2011 Dec; 30(12):1011-7.
    View in: PubMed
    Score: 0.098
  20. Patient-reported outcomes in chronic gout: a report from OMERACT 10. J Rheumatol. 2011 Jul; 38(7):1452-7.
    View in: PubMed
    Score: 0.095
  21. Tophus measurement as an outcome measure for clinical trials of chronic gout: progress and research priorities. J Rheumatol. 2011 Jul; 38(7):1458-61.
    View in: PubMed
    Score: 0.095
  22. Bringing it all together: a novel approach to the development of response criteria for chronic gout clinical trials. J Rheumatol. 2011 Jul; 38(7):1467-70.
    View in: PubMed
    Score: 0.095
  23. Quality of life and disability in patients with treatment-failure gout. J Rheumatol. 2009 May; 36(5):1041-8.
    View in: PubMed
    Score: 0.081
  24. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009 Feb; 48(2):188-94.
    View in: PubMed
    Score: 0.080
  25. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008 Nov 15; 59(11):1540-8.
    View in: PubMed
    Score: 0.079
  26. Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial. Arthritis Rheumatol. 2022 09; 74(9):1593-1601.
    View in: PubMed
    Score: 0.051
  27. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther. 2013 Sep 26; 15(5):R137.
    View in: PubMed
    Score: 0.028
  28. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011 Aug 17; 306(7):711-20.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.